Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RN1201
- Development stage
- Phase 1
- Lead developer
- AlloRunning Therapeutics
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
RN1201 is an investigational allogeneic cell therapy designed for the treatment of antibody-mediated diseases and certain autoimmune diseases refractory to standard therapies. The product consists of genetically modified immune cells targeting B-cell maturation antigen (BCMA) and CD19, which are key markers for B cell lineage and function. Its intended mechanism is to deplete pathogenic B cells, thereby suppressing aberrant antibody production. Patients typically receive RN1201 infusion following a lymphodepletion regimen. The drug is being evaluated for safety, response rate, B-cell depletion, and immune reconstitution in clinical studies.
- Brand names
- RN1201RN-1201RN 1201
- Other names
- RN1201RN-1201RN 1201
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on RN1201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RN1201.